SE509801C2 - Komplex av polyadeninsyra Poly(a) och polyuridinsyra Poly(U) - Google Patents

Komplex av polyadeninsyra Poly(a) och polyuridinsyra Poly(U)

Info

Publication number: SE509801C2
Authority: SE; Sweden
Prior art keywords: poly; complex; aids; hiv; cells
Prior art date: 1991-04-16

Application number

SE9201207A

Other languages

English (en)

Swedish (sv)

Other versions

SE9201207L (sv

SE9201207D0 (sv

Inventor

Ara G Hovanessian

De Paillette Evelyne Deschamps

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-16

Filing date

1992-04-15

Publication date

1999-03-08

1992-04-15 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

1992-04-15 Publication of SE9201207D0 publication Critical patent/SE9201207D0/xx

1992-10-17 Publication of SE9201207L publication Critical patent/SE9201207L/xx

1999-03-08 Publication of SE509801C2 publication Critical patent/SE509801C2/sv

Links

108091034057 RNA (poly(A)) Proteins 0.000 title claims abstract description 46
239000002253 acid Substances 0.000 title 2
208000030507 AIDS Diseases 0.000 claims abstract description 20
241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 8
239000003795 chemical substances by application Substances 0.000 claims abstract description 7
208000015181 infectious disease Diseases 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
229940079593 drug Drugs 0.000 claims 1
239000003085 diluting agent Substances 0.000 abstract description 4
230000001225 therapeutic effect Effects 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 abstract 2
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 22
102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 13
101710142246 External core antigen Proteins 0.000 description 9
241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
238000002474 experimental method Methods 0.000 description 5
241000700605 Viruses Species 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
102100034349 Integrase Human genes 0.000 description 3
108010067390 Viral Proteins Proteins 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000000034 method Methods 0.000 description 3
229940124321 AIDS medicine Drugs 0.000 description 2
101710132601 Capsid protein Proteins 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
108010015780 Viral Core Proteins Proteins 0.000 description 2
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
108010041397 CD4 Antigens Proteins 0.000 description 1
102100032918 Chromobox protein homolog 5 Human genes 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000797581 Homo sapiens Chromobox protein homolog 5 Proteins 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
101100528457 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RMP1 gene Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
229960000523 zalcitabine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SE9201207A 1991-04-16 1992-04-15 Komplex av polyadeninsyra Poly(a) och polyuridinsyra Poly(U) SE509801C2 (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB919108085A GB9108085D0 (en)	1991-04-16	1991-04-16	Complexes of polyadenylic acid with polyuridylic acid

Publications (3)

Publication Number	Publication Date
SE9201207D0 SE9201207D0 (sv)	1992-04-15
SE9201207L SE9201207L (sv)	1992-10-17
SE509801C2 true SE509801C2 (sv)	1999-03-08

Family

ID=10693367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9201207A SE509801C2 (sv)	1991-04-16	1992-04-15	Komplex av polyadeninsyra Poly(a) och polyuridinsyra Poly(U)

Country Status (19)

Country	Link
US (2)	US5756477A (da)
EP (1)	EP0509906A1 (da)
JP (1)	JPH05262653A (da)
KR (1)	KR100233393B1 (da)
AU (1)	AU656574B2 (da)
BE (1)	BE1004857A3 (da)
CA (1)	CA2066134C (da)
CH (1)	CH684521A5 (da)
DK (1)	DK51192A (da)
DZ (1)	DZ1570A1 (da)
FR (1)	FR2675384B1 (da)
GB (2)	GB9108085D0 (da)
IE (1)	IE921208A1 (da)
LU (1)	LU88102A1 (da)
MY (1)	MY108106A (da)
NO (1)	NO921513L (da)
OA (1)	OA09577A (da)
SE (1)	SE509801C2 (da)
ZA (1)	ZA922699B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6734192B1 (en) *	1999-08-23	2004-05-11	Mp-1 Inc.	Treatment of viral infections
US7875283B2 (en) *	2000-04-13	2011-01-25	Advanced Cardiovascular Systems, Inc.	Biodegradable polymers for use with implantable medical devices
US7186789B2 (en)	2003-06-11	2007-03-06	Advanced Cardiovascular Systems, Inc.	Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
US20060135253A1 (en) *	2004-09-10	2006-06-22	Jeffrey George	Gaming system and method for providing entry to a contest

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4940954B1 (da) *	1970-02-16	1974-11-06
US3796631A (en) *	1970-11-09	1974-03-12	Choay Sa	Processes for preparing polynucleotides
IL37076A (en) *	1971-06-16	1974-05-16	Littauer U	A method for stepwise synthesis of oligoribonucleotides of defined sequence using 2'(3')-o-acyl-nucleoside diphosphates and polynucleotide phosphorylase
US4124702A (en) *	1971-07-06	1978-11-07	Merck & Co., Inc.	Polynucleotides active as inducers of interferon production in living animal cells
JPS524633B2 (da) *	1972-07-21	1977-02-05
GB1435571A (en) *	1973-04-02	1976-05-12	Searle & Co	Polynucleotides
DE2319495C2 (de) *	1973-04-17	1985-01-10	Yeda Research And Development Co., Ltd., Rehovot	Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4024222A (en) *	1973-10-30	1977-05-17	The Johns Hopkins University	Nucleic acid complexes
FR2252350A1 (en) *	1973-11-22	1975-06-20	Choay Sa	Polynucleotide phosphorylase - extraction from E coli, fixation on sepharose, and use in preparing polynucleotides
JPS50107187A (da) *	1974-02-08	1975-08-23
US4006059A (en) *	1974-07-29	1977-02-01	Purdue Research Foundation	Hydrophobic noncovalent binding of proteins to support materials
US4000098A (en) *	1974-08-16	1976-12-28	Palo Alto Medical Research Foundation	Separation of proteins by hydrophobic adsorption
US4024241A (en) *	1974-09-27	1977-05-17	The United States Of America As Represented By The Secretary Of Health, Education And Welfare	Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4075195A (en) *	1976-08-31	1978-02-21	Kraft, Inc.	Debittered protein product and method for manufacture
SU619508A1 (ru) *	1976-12-07	1978-08-15	Предприятие П/Я Г-4740	Способ получени полинуклеотидов, обладающих полирибонуклеотидфосфорилазной активностью
JPS5519239A (en) *	1978-07-28	1980-02-09	Green Cross Corp:The	Interferon-producing attractant
JPS5618597A (en) *	1979-07-23	1981-02-21	Mitsubishi Chem Ind Ltd	Production of oligonucleotide
US4379843A (en) *	1981-01-26	1983-04-12	Peter Cashion	Immobilization of polynucleotides and polypeptides with tritylated polysaccharides
US4400375A (en) *	1981-11-23	1983-08-23	Eli Lilly And Company	Tobramycin-double stranded RNA complex suitable for inducing interferon
EP0113162B1 (en) *	1982-09-16	1989-07-19	Hem Research, Inc.	Anti-proliferative action of dsnras on tumor cells
US4617376A (en) *	1985-07-01	1986-10-14	Eli Lilly And Company	Process for recovering glucagon from pancreas glands
CA1326450C (en) *	1985-08-26	1994-01-25	William A. Carter	Modulation of aids virus-related events by double stranded rnas (dsrnas)
US4820696A (en) *	1985-08-26	1989-04-11	Hem Research, Inc.	Modulation of aids virus-related events by double-stranded RNAS
US5063209A (en) *	1985-08-26	1991-11-05	Hem Research, Inc.	Modulation of aids virus-related events by double-stranded RNAs
US4945082A (en) *	1985-08-26	1990-07-31	Hem Research, Inc.	Controlled dsRNA therapy for human viral infections
US4795744A (en) *	1986-07-17	1989-01-03	Hem Research, Inc.	Modulation of AIDS virus-related events by double-stranded RNAS
US4771128A (en) *	1986-10-10	1988-09-13	Cetus Corporation	Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4950652A (en) *	1987-03-23	1990-08-21	Hem Research, Inc.	dsRNAs for combination therapy in the treatment of viral diseases
US5091374A (en) *	1987-07-17	1992-02-25	Hem Research Inc.	Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
AU1820388A (en) *	1987-07-17	1989-01-19	Hem Research, Inc.	Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
AU1820588A (en) *	1987-07-17	1989-01-19	Hem Research, Inc.	Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
GB8725606D0 (en) *	1987-11-02	1987-12-09	Soc D Etudes Prod Chimique	Preparation polynucleotides
US4963532A (en) *	1987-11-25	1990-10-16	Hem Research, Inc.	dsRNA-based prevention of viral escape
ES2066847T3 (es) *	1988-07-07	1995-03-16	Hem Pharma Corp	Diagnostico y tratamiento del sindrome de fatiga cronica.
JP2619710B2 (ja) *	1989-02-27	1997-06-11	日本製紙株式会社	２′，３′−ジデオキシプリンヌクレオシド類の製造方法

1991
- 1991-04-16 GB GB919108085A patent/GB9108085D0/en active Pending
1992
- 1992-04-09 GB GB9207798A patent/GB2255504A/en not_active Withdrawn
- 1992-04-10 CH CH1177/92A patent/CH684521A5/fr not_active IP Right Cessation
- 1992-04-12 DZ DZ920036A patent/DZ1570A1/fr active
- 1992-04-13 ZA ZA922699A patent/ZA922699B/xx unknown
- 1992-04-15 EP EP92401045A patent/EP0509906A1/fr not_active Withdrawn
- 1992-04-15 KR KR1019920006270A patent/KR100233393B1/ko not_active Expired - Fee Related
- 1992-04-15 FR FR9204606A patent/FR2675384B1/fr not_active Expired - Fee Related
- 1992-04-15 SE SE9201207A patent/SE509801C2/sv not_active IP Right Cessation
- 1992-04-15 DK DK051192A patent/DK51192A/da not_active Application Discontinuation
- 1992-04-15 BE BE9200348A patent/BE1004857A3/fr not_active IP Right Cessation
- 1992-04-15 NO NO92921513A patent/NO921513L/no unknown
- 1992-04-15 AU AU14909/92A patent/AU656574B2/en not_active Ceased
- 1992-04-15 CA CA002066134A patent/CA2066134C/en not_active Expired - Fee Related
- 1992-04-15 JP JP4095140A patent/JPH05262653A/ja not_active Ceased
- 1992-04-15 IE IE120892A patent/IE921208A1/en unknown
- 1992-04-15 MY MYPI92000650A patent/MY108106A/en unknown
- 1992-04-16 LU LU88102A patent/LU88102A1/fr unknown
- 1992-04-16 OA OA60187A patent/OA09577A/fr unknown
1996
- 1996-01-04 US US08/582,658 patent/US5756477A/en not_active Expired - Fee Related
1997
- 1997-03-13 US US08/816,643 patent/US5736525A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO921513L (no)	1992-10-19
JPH05262653A (ja)	1993-10-12
ZA922699B (en)	1992-12-30
GB2255504A (en)	1992-11-11
EP0509906A1 (fr)	1992-10-21
CA2066134C (en)	2002-11-19
DK51192D0 (da)	1992-04-15
SE9201207L (sv)	1992-10-17
FR2675384B1 (fr)	1995-09-15
AU656574B2 (en)	1995-02-09
LU88102A1 (fr)	1992-10-15
KR920019363A (ko)	1992-11-19
AU1490992A (en)	1992-10-22
DK51192A (da)	1992-10-17
OA09577A (fr)	1993-01-31
FR2675384A1 (fr)	1992-10-23
IE921208A1 (en)	1992-10-21
SE9201207D0 (sv)	1992-04-15
BE1004857A3 (fr)	1993-02-09
CH684521A5 (fr)	1994-10-14
KR100233393B1 (ko)	1999-12-01
MY108106A (en)	1996-08-15
GB9207798D0 (en)	1992-05-27
US5756477A (en)	1998-05-26
GB9108085D0 (en)	1991-06-05
NO921513D0 (no)	1992-04-15
US5736525A (en)	1998-04-07
CA2066134A1 (en)	1992-10-17
DZ1570A1 (fr)	2002-02-17

Legal Events

Date	Code	Title	Description
2009-12-15	NUG	Patent has lapsed

Publication	Publication Date	Title
Jolly et al.	2010	Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells
Pahwa et al.	1985	Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.
DE69222303T2 (de)	1998-01-22	Kationisierte antikörper gegen intrazelluläre eiweisse
Hoover et al.	1987	Experimental transmission and pathogenesis of immunodeficiency syndrome in cats
DE69311427T2 (de)	1998-02-12	Synthetische Polypeptide als Inhibitoren von HIV-1
DE69230068T2 (de)	2000-03-09	Immunogene verbindungen mit spezifischem anti-cytokin effekt, methode zur herstellung, pharmazeutische zusammensetzung und reaktionskit der diese enthält
Haraguchi et al.	1995	Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections.
SE509801C2 (sv)	1999-03-08	Komplex av polyadeninsyra Poly(a) och polyuridinsyra Poly(U)
DE60118592T2 (de)	2007-05-16	Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus
Schreck et al.	1992	Selection of a muramyl peptide based on its lack of activation of nuclear factor-κB as a potential adjuvant for AIDS vaccines
DE69626681T2 (de)	2004-02-12	Konditionell-replizierende virale vektoren und ihre verwendung.
KR20000069296A (ko)	2000-11-25	항바이러스 활성을 갖는 살비아 종의 추출물
DE19813802A1 (de)	1999-11-11	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
KR900005170B1 (ko)	1990-07-20	항레트로바이러스 약제
DE3724951A1 (de)	1989-02-09	Arzneimittel, enthaltend modifizierte desoxyribonukleinsaeure und dessen verwendung
WO1991018454A1 (en)	1991-11-28	Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
JP2002533400A (ja)	2002-10-08	Ｈｉｖ及び他のウイルス感染の治療及び予防
US20050148541A1 (en)	2005-07-07	Treatment and prevention of HIV and other viral infections
RU2203071C2 (ru)	2003-04-27	Применение белков в качестве антиретровирусных агентов
JP2669937B2 (ja)	1997-10-29	ジドブジンに対するｈｉｖ−１株の耐性を逆転させる方法
Carlier et al.	2000	Ion channel activation by SPC3, a peptide derived from the HIV‐1 gp120 V3 loop
CN1051451C (zh)	2000-04-19	抗aids病毒的药物组合物
Kocięcka et al.	1989	The effect of Thymus Factor X (TFX Polfa) on the clinical course of human trichinellosis
NZ242264A (en)	1995-02-24	Polyadenylic acid/polyuridylic acid complexes in pharmaceutical compositions
DE19908766C2 (de)	2001-02-15	Verwendung synthetischer Vpr-Peptide des Humanen Immundefizienzvirus Typ 1 (HIV-1) zur Entwicklung von therapeutischen und diagnostischen Reagenzien